LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | PD173074 | 3.33 | uM | LJP6 | 72 | hr | 1476 | 4220 | 3643 | 1.1605 | 1.2471 |
| SK-BR-3 | R406 | 1.11 | uM | LJP6 | 72 | hr | 1476 | 4206 | 3643 | 1.1578 | 1.2443 |
| MCF7 | PIK-93 | 0.12 | uM | LJP5 | 72 | hr | 1235 | 4937 | 4267 | 1.1567 | 1.1690 |
| MCF7 | PD173074 | 1.11 | uM | LJP6 | 72 | hr | 1235 | 4692 | 4056 | 1.1566 | 1.1765 |
| MCF7 | PIK-93 | 0.04 | uM | LJP5 | 72 | hr | 1235 | 4925 | 4267 | 1.1553 | 1.1686 |
| MCF7 | Pelitinib | 0.12 | uM | LJP5 | 72 | hr | 1235 | 4915 | 4267 | 1.1518 | 1.1635 |
| SK-BR-3 | XL147 | 3.33 | uM | LJP5 | 72 | hr | 1476 | 4341 | 3772 | 1.1507 | 1.2181 |
| SK-BR-3 | SU11274 | 0.04 | uM | LJP5 | 72 | hr | 1476 | 4337 | 3772 | 1.1497 | 1.2170 |
| MDA-MB-231 | PD173074 | 0.04 | uM | LJP6 | 72 | hr | 868 | 4084 | 3556 | 1.1488 | 1.1413 |
| MCF7 | SB590885 | 1.11 | uM | LJP5 | 72 | hr | 1235 | 4899 | 4267 | 1.1480 | 1.1604 |
| SK-BR-3 | Saracatinib | 0.12 | uM | LJP6 | 72 | hr | 1476 | 4158 | 3643 | 1.1448 | 1.2253 |
| Hs 578T | Nilotinib | 0.37 | uM | LJP5 | 72 | hr | 929 | 3705 | 3237 | 1.1445 | 1.1555 |
| BT-20 | Enzastaurin | 1.11 | uM | LJP5 | 72 | hr | 1657 | 6392 | 5588 | 1.1441 | 1.1597 |
| MCF7 | SU11274 | 0.04 | uM | LJP5 | 72 | hr | 1235 | 4880 | 4267 | 1.1441 | 1.1561 |
| Hs 578T | PLX-4720 | 0.37 | uM | LJP5 | 72 | hr | 929 | 3703 | 3237 | 1.1438 | 1.1546 |
| MDA-MB-231 | Gefitinib | 0.04 | uM | LJP6 | 72 | hr | 868 | 4066 | 3556 | 1.1438 | 1.1368 |
| SK-BR-3 | XL147 | 0.12 | uM | LJP5 | 72 | hr | 1476 | 4313 | 3772 | 1.1433 | 1.2076 |
| SK-BR-3 | R406 | 3.33 | uM | LJP6 | 72 | hr | 1476 | 4165 | 3643 | 1.1424 | 1.2146 |
| MCF7 | Imatinib | 0.37 | uM | LJP6 | 72 | hr | 1235 | 4629 | 4056 | 1.1420 | 1.1596 |
| MDA-MB-231 | SU11274 | 0.04 | uM | LJP5 | 72 | hr | 868 | 3885 | 3410 | 1.1393 | 1.1365 |
| MCF7 | Linifanib | 0.12 | uM | LJP6 | 72 | hr | 1235 | 4619 | 4056 | 1.1392 | 1.1579 |
| SK-BR-3 | Enzastaurin | 0.04 | uM | LJP5 | 72 | hr | 1476 | 4294 | 3772 | 1.1386 | 1.2015 |
| MCF7 | Gefitinib | 0.04 | uM | LJP6 | 72 | hr | 1235 | 4620 | 4056 | 1.1386 | 1.1569 |
| BT-20 | Selumetinib | 0.04 | uM | LJP6 | 72 | hr | 1657 | 6126 | 5383 | 1.1379 | 1.1577 |
| MDA-MB-231 | Withaferin A | 0.04 | uM | LJP5 | 72 | hr | 868 | 3875 | 3410 | 1.1376 | 1.1350 |